Non-Small Cell Carcinoma of Lung, TNM Stage 4 Clinical Trial
Official title:
TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases. Never smokers with lung cancer typically present with different molecular profiles from that of smokers, which results in prognostic and therapeutic implications. Molecular changes in NSCLC that have therapeutic significance include mutations in the epidermal growth factor receptor (EGFR) and rearrangements in the anaplastic lymphoma kinase (ALK) gene. These driver mutations typically are present in lung tumors found in never or light smokers. The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone, 12.3 vs. 10.3 months respectively. Results from the POINTBREAK trial demonstrated that carboplatin + pemetrexed + bevacizumab is an alternative option to carboplatin + paclitaxel + bevacizumab, with comparable survival but less toxicity. In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. The PD-1 inhibitor nivolumab and the PD-L1 inhibitor atezolizumab have shown prolonged survival in comparison to docetaxel in patients who previously progressed with chemotherapy, irrespective of PD-L1 expression. Thus, this study combines immunotherapeutic agent atezolozumab with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin and pemetrexed).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04776083 -
Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
|
Phase 3 | |
| Active, not recruiting |
NCT03288870 -
Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05919264 -
FOG-001 in Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03042221 -
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
|
||
| Recruiting |
NCT05274451 -
A Study to Investigate LYL797 in Adults With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05372081 -
Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
|
||
| Recruiting |
NCT03774732 -
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT03406468 -
Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04856176 -
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
|
Phase 2 | |
| Terminated |
NCT02967133 -
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT04710459 -
Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC
|
N/A | |
| Recruiting |
NCT03605602 -
A Real World Study Based on NGS (TRUMPRWS)
|